Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Ondansetron in early-onset alcoholism

Return to PJ Online Home Page

The Pharmaceutical Journal Vol 265 No 7113p355
September 9, 2000 Clinical

Ondansetron in early-onset alcoholism

Ondansetron is an effective treatment for patients with early-onset alcoholism, according to researchers in the US. Dr Bankole Johnson (University of Texas Health Science Center, US) and colleagues undertook a randomised, controlled trial in 271 patients with diagnosed alcoholism, comparing the efficacy of ondansetron (1 µg/kg, 4µg/kg or 16µg/kg) with placebo on drinking outcomes (Journal of the American Medical Association 2000;284:963). The study was designed to test the hypothesis that individuals whose alcoholism developed before the age of 25 (early-onset alcoholism) might be responsive to treatment with a selective serotonergic agent. Ondansetron is a 5-HT3 antagonist.
Patients with early-onset and late-onset alcoholism were equally represented in the study. All patients also participated in weekly group cognitive behavioural therapy.
Ondansetron significantly reduced alcohol consumption and increased abstinence among patients with early-onset but not late-onset alcoholism, say the researchers. Drinking outcomes were most markedly improved in "early-onset" patients who received the 4µg/kg dose. These patients had on average 1.56 drinks per day compared with 3.30 drinks in the placebo group. At this dose, ondansetron was superior to placebo in increasing percentage of days abstinent (70.1 compared with 50.2; p=0.02).
Plasma carbohydrate deficient transferrin, a marker of transient alcohol consumption, was measured to confirm the differences in reported alcohol consumption. The researchers hypothesise that "reduced 5-HT neurotransmission in patients with early-onset compared with late-onset alcoholism, differentially upregulates postsynaptic 5-HT3 receptors, a blockade of which may account for ondansetron's differential treatment effectiveness."
In an accompanying editorial (ibid p1016), Dr Henry Kranzler (Alcohol Research Center, Farmington, US) comments: "The study exemplifies a potential role in alcoholism treatment for a medication with a well-defined mechanism of action, reinforcing the rational effort to identify medications to treat the disorder." He adds: "These findings also suggest a potential for the development of pharmacogenetic strategies to treat alcohol dependence."
A spokeswoman for Glaxo Wellcome, the UK manufacturer of Zofran (ondansetron), told The Journal that the company was still assessing data from trials testing ondansetron as a treatment for early-onset alcoholism. A decision on whether to pursue this line of research would be made once all the data had been evaluated.

Potential for antisickness drug in early-onset alcoholism
Potential for antisickness drug in early-onset alcoholism

Citation: The Pharmaceutical Journal URI: 20002764

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.